Skip to Content
Merck
  • Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.

Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.

Molecular cancer (2013-09-28)
Anja Pucer, Vesna Brglez, Christine Payré, Jože Pungerčar, Gérard Lambeau, Toni Petan
ABSTRACT

Alterations in lipid metabolism are inherent to the metabolic transformations that support tumorigenesis. The relationship between the synthesis, storage and use of lipids and their importance in cancer is poorly understood. The human group X secreted phospholipase A2 (hGX sPLA2) releases fatty acids (FAs) from cell membranes and lipoproteins, but its involvement in the regulation of cellular FA metabolism and cancer is not known. Here we demonstrate that hGX sPLA2 induces lipid droplet (LD) formation in invasive breast cancer cells, stimulates their proliferation and prevents their death on serum deprivation. The effects of hGX sPLA2 are shown to be dependent on its enzymatic activity, are mimicked by oleic acid and include activation of protein kinase B/Akt, a cell survival signaling kinase. The hGX sPLA2-stimulated LD biogenesis is accompanied by AMP-activated protein kinase (AMPK) activation, up-regulation of FA oxidation enzymes and the LD-coating protein perilipin 2, and suppression of lipogenic gene expression. Prolonged activation of AMPK inhibited hGX sPLA2-induced LD formation, while etomoxir, an inhibitor of FA oxidation, abrogated both LD formation and cell survival. The hGX sPLA2-induced changes in lipid metabolism provide a minimal immediate proliferative advantage during growth under optimal conditions, but they confer to the breast cancer cells a sustained ability to resist apoptosis during nutrient and growth factor limitation. Our results identify hGX sPLA2 as a novel modulator of lipid metabolism that promotes breast cancer cell growth and survival by stimulating LD formation and FA oxidation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(+)-Etomoxir sodium salt hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
S32826 disodium salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Bezafibrate, ≥98%, solid
Sigma-Aldrich
AICAR, ≥98% (HPLC), powder